WATERTOWN, Mass., Aug. 31 /PRNewswire/ -- Enanta Pharmaceuticals today
announced that it has raised $20 million in new financing. The Company has
also initiated a Phase 1 clinical trial in the United States for its community
antibiotic candidate, EP-013420.
Participants in the financing included Shionogi & Co. LTD, as well as
returning investors Techno Venture Management, Oxford Bioscience Partners,
BioVentures Investors and Global Biomedical Partners. The funding will be
used to advance EP-013420 in the clinic and to progress the company's
discovery-stage anti-infective programs.
First in its class, EP-013420 is a Bridged Bicyclic Ketolide (BBK) that
was designed by Enanta to have optimal pharmacokinetics and to provide broad
treatment against respiratory pathogens, including several multi-drug
resistant strains for which traditional macrolides, penicillins, and
fluoroquinolones are no longer effective. In this trial, EP-013420 will be
evaluated for its pharmacokinetics, safety and tolerability in healthy
volunteers. In July 2004, Enanta exclusively licensed the Asia territory
rights for EP-013420 to Shionogi & Co., LTD., of Osaka, Japan.
"This clinical trial marks an important milestone for Enanta as we have
translated our chemistry and drug discovery expertise into a very important
new clinical-stage product with blockbuster potential to satisfy a growing
unmet medical need in the community setting," said Jay Luly, Ph.D., President
and CEO. "The ambitious pre-clinical product-profile we have achieved with
EP-013420 will provide us the opportunity to pursue multiple indications and
position this drug candidate as best-in-class."
"There is a tremendous need for next generation antibiotics to overcome
the growing threat of bacterial resistance in the treatment of community
respiratory tract infections," stated infectious disease specialist Robert C.
Moellering, Jr., M.D., Herrman Blumgart Professor of Medicine at Harvard
Medical School and Beth Israel Deaconess Medical Center and Enanta Clinical
"Enanta's novel BBK antibiotics offer the promise of broader coverage
against many of these resistant strains with the potential of improved safety
and efficacy, and more convenient dosing," said Yat Sun Or, Ph.D., Senior Vice
President, Research and Development.
Enanta is developing EP-013420 for the treatment of community respiratory
tract infections with potential indications for community acquired pneumonia,
acute exacerbation of chronic bronchitis, acute sinusitis,
tonsilitis/pharyngitis, and otitis media. EP-013420 is a first-in-class
Bridged Bicyclic Ketolide antibiotic that is the result of Enanta's innovative
medicinal chemistry approach to creating novel and proprietary chemical
structures. Preclinical studies have shown an excellent pharmacokinetic
profile for EP-013420 and an improved activity profile relative to currently
marketed macrolides and ketolides, including activity against many strains of
resistant S. pneumoniae. This is the most commonly implicated bacteria in
respiratory infections, responsible for 45% of the cases of community acquired
pneumonia (CAP) and 34% of acute sinusitis. Nearly one-third of S. pneumoniae
infections in the US are resistant to penicillin and 31% are resistant to the
macrolide antibiotic erythromycin. S. pneumoniae resistance is more common in
Asia, where 53% of S. pneumoniae infections are penicillin resistant and 80%
are erythromycin resistant.
The global respiratory antibiotic market was approximately $12 billion in
2002. Three major antibiotic classes dominate the respiratory antibiotic
market: macrolides, beta-lactams, and quinolones. Of these classes, several
respiratory antibiotics generate annual sales well in excess of $1 billion.
Worldwide sales of macrolide drugs amounted to approximately $5.64 billion in
Enanta Pharmaceuticals is a research and development company that uses its
novel chemistry approach and drug discovery capabilities to create best in
class small molecule drugs in the anti-infective field. The heart of Enanta
is its commitment to innovative chemistry that surpasses traditional medicinal
chemistry approaches. The Company's successful integration of chemistry with
biology has created a new class of macrolide and ketolide antibiotics that
overcome bacterial resistance. Additionally, Enanta has discovered antiviral
agents targeted against the Hepatitis C virus (HCV). Enanta is a privately
held company with offices in Watertown, MA. More information about the
company can be found at http://www.enanta.com.
For Investor Relations, please contact:
Senior Vice President and Chief Financial Officer
For Public Relations, please contact MacDougall Biocommunications:
SOURCE Enanta Pharmaceuticals